Condition (MeSH)
Nevus, Pigmented
ClinicalTrials.gov lists 21 trials for Nevus, Pigmented or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 21 trials are tagged with Nevus, Pigmented itself; the rest are tagged with a narrower condition beneath it.
When did Nevus, Pigmented trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nevus, Pigmented trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Not applicable | 5 |
| Observational | 14 |
How many Nevus, Pigmented trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Completed | 9 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nevus, Pigmented trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| AI Labs Group S.L | 1 |
| Immunocore Ltd | 1 |
| Istanbul Training and Research Hospital | 1 |
Which drugs are being tested for Nevus, Pigmented? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Tebentafusp | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Samples | 2 |
| Investigators Choice | 1 |
| Tebentafusp with Pembrolizumab | 1 |
| L:Lidocaine | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Nevus, Pigmented? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening? | European journal of cancer (Oxford, England : 1990) | 2023 | Yes |
| Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2020 | Yes |
| Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. | Cancer discovery | 2018 | Yes |
| Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. | Journal of the American Academy of Dermatology | 2017 | Yes |
| Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. | BMJ (Clinical research ed.) | 2017 | Yes |
Showing 5 of 40 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.